<DOC>
	<DOCNO>NCT01196780</DOCNO>
	<brief_summary>This observational study ass efficacy safety MabThera/Rituxan ( Rituximab ) patient active rheumatoid arthritis inadequate response intolerant anti-TNF therapy . Data collect patient initiated MabThera/Rituxan therapy accord standard care routine clinical practice . For patient data collect 92 week .</brief_summary>
	<brief_title>An Observational Study MabThera/Rituxan ( Rituximab ) Patients With Active Rheumatoid Arthritis Who Have Inadequate Response Anti-TNF Therapy ( REPEAT )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Active Rheumatoid Arthritis Inadequate response antiTNF Eligible MabThera/Rituxan therapy accord physician 's decision According Summary Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>